• O-GlcNAcylation Regulates HUWE1-TfR1 Axis in Preeclampsia Fe

  2026-08-06

  This study delineates how O-GlcNAc modification of HUWE1 orchestrates the ubiquitination and degradation of transferrin receptor 1 (TfR1), thereby restraining ferroptosis and supporting trophoblast syncytialization in preeclampsia. The findings propose the O-GlcNAc–HUWE1–TfR1 pathway as a mechanistically precise target for placental dysfunction and iron-driven pathology.

• Super-Enhancer–FOXA1–SLC7A11 Axis Controls Disulfidptosis in

  2026-08-05

  Kang et al. reveal that a super-enhancer regulates SLC7A11 via FOXA1, driving disulfidptosis and tumor progression in prostate cancer. This mechanistic insight identifies a novel epigenetic vulnerability and suggests new avenues for targeted research on cell death regulation in cancer.

• Angiotensin II: Strategic Leverage for Vascular Remodeling M

  2026-08-05

  This article explores the mechanistic depth and translational potential of Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) in vascular research, offering strategic guidance for modeling hypertension, cardiovascular remodeling, and vascular smooth muscle cell hypertrophy. Drawing on recent advances—including the therapeutic modulation of Ang II-induced injury by benzyl alcohol—this piece provides protocol insights, critical analysis of the competitive research landscape, and a forward-looking perspective for translational investigators. By contextualizing APExBIO's Angiotensin II within both foundational and emerging paradigms, we highlight actionable strategies that elevate experimental rigor and translational relevance beyond typical product overviews.

• Radicicol: Advancing Hsp90 Inhibition in Translational Resea

  2026-08-04

  Explore how Radicicol, a potent Hsp90 inhibitor from APExBIO, enables precision control of cell fate, inflammation, and immune modulation. This article integrates mechanistic insights, strategic protocol guidance, and translational considerations—bridging bench discovery to next-generation therapeutic innovation.

• Elobixibat Hydrate: Optimizing IBAT Inhibitor Workflows in G

  2026-08-04

  Elobixibat hydrate stands out as a highly selective ileal bile acid transporter inhibitor, empowering researchers to dissect and modulate enterohepatic and metabolic pathways in chronic constipation and metabolic disease models. This guide details robust experimental workflows, troubleshooting strategies, and translational insights for maximizing data quality with APExBIO’s Elobixibat hydrate.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual Fluorescence for Macro

  2026-08-03

  Explore how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers real-time, dual-fluorescence mRNA delivery and translation efficiency assays in macrophages. This article uniquely analyzes carbohydrate-targeted delivery, practical protocol design, and translational insights for advanced gene regulation.

• 3-Bromopyruvate Restores Cetuximab Sensitivity via Ferroptos

  2026-08-03

  This study demonstrates that co-treatment with 3-bromopyruvate and cetuximab overcomes resistance in colorectal cancer cells by inducing autophagy-dependent ferroptosis and apoptosis. The findings highlight mechanistic links between FOXO3a signaling, cell death pathways, and therapeutic strategies for resistant CRC.

• Applied Workflows with Ertugliflozin (PF-04971729) in Diabet

  2026-08-02

  Ertugliflozin (PF-04971729) stands out for its unparalleled selectivity in SGLT2 inhibition, enabling precise mechanistic modeling of renal glucose transport and cardiovascular endpoints. This guide delivers actionable protocols, troubleshooting insights, and evidence-based recommendations to optimize diabetes mellitus research and beyond.

• Vitamin C Inhibits ROS/NF-κB Pathway to Delay Cochlear Cell

  2026-08-01

  This study demonstrates that vitamin C (ascorbic acid) significantly ameliorates D-galactose-induced senescence in cochlear hair cells by inhibiting the ROS/NF-κB signaling pathway. These findings highlight a novel mechanism by which vitamin C may help counteract age-related hearing loss and suggest new directions for targeted senescence interventions.

• Talabostat Mesylate (PT-100): Applied Workflows in Cancer an

  2026-07-31

  Talabostat mesylate (PT-100) uniquely enables researchers to dissect DPP4 and FAP inhibition for precise tumor microenvironment modulation and immune cell interrogation. This article translates the latest CARD8 inflammasome research and advanced protocol optimizations into actionable guidance for robust, reproducible preclinical studies.

• Ionomycin Free Acid: Precision Calcium Ionophore for FAK & T

  2026-07-31

  Ionomycin free acid empowers researchers to modulate intracellular calcium with unmatched control, fueling breakthroughs in FAK pathway and triple negative breast cancer (TNBC) studies. Discover advanced workflows, troubleshooting strategies, and practical insights for leveraging this APExBIO calcium ionophore in cutting-edge cancer and developmental biology research.

• Redefining mRNA Reporter Performance: Strategy Meets Mechani

  2026-07-30

  Explore the mechanistic advances and translational strategies enabled by EZ Cap™ Firefly Luciferase mRNA. This article bridges rigorous molecular insight with actionable guidance for researchers, integrating breakthrough evidence on mRNA-LNP delivery, oxidative stress mitigation, and the evolving landscape of bioluminescent reporter technologies.

• RIPA Lysis Buffer (Strong): Reliable Protein Extraction for

  2026-07-30

  This article addresses major challenges in cell and tissue protein extraction for viability, proliferation, and cytotoxicity assays. Using real laboratory scenarios, we show how 'RIPA Lysis Buffer (Strong)' (SKU K1020) provides reproducible, data-driven solutions for Western blotting and immunoprecipitation workflows. Evidence-backed protocol tips and vendor comparisons help maximize experimental robustness.

• Anagliptin Induces Vasorelaxation via Kv Channel and SERCA A

  2026-07-29

  This study reveals that Anagliptin (SK-0403), a DPP-4 inhibitor, directly induces vasorelaxation in rabbit aorta through activation of voltage-dependent K+ (Kv) channels and the SERCA pump, independent of endothelium or classic cAMP/cGMP signaling. These findings clarify novel, endothelium-independent vascular effects, with implications for cardiovascular safety and mechanism-focused diabetes research.

• MOG (35-55): Mechanistic Leverage for Translational MS Resea

  2026-07-29

  This thought-leadership article unpacks how APExBIO’s MOG (35-55) Peptide enables next-generation autoimmune encephalomyelitis research, integrating recent discoveries on interferon pathway regulation and PARP7 inhibition. We provide translational researchers with mechanistic clarity, protocol guidance, and a forward-looking perspective to optimize multiple sclerosis models and accelerate therapeutic discovery.

454 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page